# Takeda Pharmaceutical Co Ltd: overview TAK · NYSE · CIK 1395064 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/tak.md) · [Financials](/companies/tak/financials.md) · [Filings](/companies/tak/filings.md) · [Insiders](/companies/tak/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-03-31) | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | [3,198](/filings/0001395064-23-000072.md) | [3,569](/filings/0001395064-24-000086.md) | [4,027](/filings/0001395064-25-000095.md) | [4,264](/filings/0001395064-25-000095.md) | [4,582](/filings/0001395064-25-000095.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [15.9%](/filings/0001395064-23-000072.md) | [12.9%](/filings/0001395064-24-000086.md) | [12.2%](/filings/0001395064-25-000095.md) | [5.0%](/filings/0001395064-25-000095.md) | [7.5%](/filings/0001395064-25-000095.md) | | Net margin | % | [11.8%](/filings/0001395064-23-000072.md) | [6.4%](/filings/0001395064-24-000086.md) | [7.9%](/filings/0001395064-25-000095.md) | [3.4%](/filings/0001395064-25-000095.md) | [2.4%](/filings/0001395064-25-000095.md) | | Diluted EPS | $ per share | [238.96](/filings/0001395064-23-000072.md) | [145.87](/filings/0001395064-24-000086.md) | [201.94](/filings/0001395064-25-000095.md) | [91.16](/filings/0001395064-25-000095.md) | [67.23](/filings/0001395064-25-000095.md) | | Free cash flow | $bn | [900](/filings/0001395064-23-000072.md) | [1,000](/filings/0001395064-24-000086.md) | [836](/filings/0001395064-25-000095.md) | [541](/filings/0001395064-25-000095.md) | [856](/filings/0001395064-25-000095.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tak/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $309.3m | 19,297,680 | | Added +193,461 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $153.9m | 9,599,302 | | Added +2,481,816 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $112.1m | 6,994,924 | | Added +525,324 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $97.0m | 6,050,771 | | Reduced −374,213 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $82.2m | 5,125,032 | | Reduced −493,696 | | [BRANDES INVESTMENT PARTNERS, LP](/funds/1015079.md) | 2026-06-30 | $72.8m | 4,539,347 | | Added +108,705 | | [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $59.8m | 3,732,924 | | Added +616,613 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $59.1m | 3,688,166 | | Added +511,745 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $41.2m | 2,568,000 | | Reduced −421,100 | | [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $35.4m | 2,207,432 | | New +2,207,432 | ## Recent filings [All 690 filings](/companies/tak/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 06:49 ET | [6-K](/filings/0001395064-26-000345.md) | Report of a foreign private issuer, period 2026-10-29 | 0001395064-26-000345 | | 2026-10-29 | 06:33 ET | [6-K](/filings/0001395064-26-000343.md) | Report of a foreign private issuer, period 2026-10-29 | 0001395064-26-000343 | | 2026-09-14 | 06:25 ET | [6-K](/filings/0001395064-26-000337.md) | Report of a foreign private issuer, period 2026-09-14 | 0001395064-26-000337 | | 2026-08-31 | 21:10 ET | [6-K](/filings/0001395064-26-000331.md) | Report of a foreign private issuer, period 2026-08-28 | 0001395064-26-000331 | | 2026-08-06 | 21:37 ET | [6-K](/filings/0001395064-26-000329.md) | Report of a foreign private issuer, period 2026-08-05 | 0001395064-26-000329 | | 2026-07-30 | 06:01 ET | [6-K](/filings/0001395064-26-000327.md) | Report of a foreign private issuer, period 2026-07-30 | 0001395064-26-000327 | | 2026-07-09 | 06:00 ET | [6-K](/filings/0001395064-26-000280.md) | Report of a foreign private issuer, period 2026-07-09 | 0001395064-26-000280 | | 2026-07-08 | 06:02 ET | [6-K](/filings/0001395064-26-000278.md) | Report of a foreign private issuer, period 2026-07-08 | 0001395064-26-000278 | | 2026-06-29 | 06:01 ET | [6-K](/filings/0001395064-26-000189.md) | Report of a foreign private issuer, period 2026-06-29 | 0001395064-26-000189 | | 2026-06-26 | 06:32 ET | [6-K](/filings/0001395064-26-000187.md) | Report of a foreign private issuer, period 2026-06-26 | 0001395064-26-000187 | ## Latest annual report [Form 20-F for the fiscal year ended Mar 31, 2026](/filings/0001395064-26-000177.md), filed Jun 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1395064 - Tickers: TAK, TKPHF - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 18:41 ET. No prices; not investment advice.